Holen Sie sich die Stockscreener-App
17.11
7.88%
1.25
Handel nachbörslich:
16.99
-0.12
-0.70%
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Analysts Unfazed By Janux’s Weaker Prostate Cancer Results - Citeline News & Insights
12/2/2025 Market UpdateWinners: XHLD, TLRY, HPPLosers: SONN, JANX, ABTCS&P 500: 0% - Trefis
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Janux tanks despite claiming positive trial results for JANX007 in mCRPC - The Pharma Letter
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Alibaba Health Information Technology (OtherALBHF) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy - geneonline.com
Janux shares halve despite still strong Phase I data - BioCentury
Janux stock falls as UBS maintains Buy rating despite disappointing data By Investing.com - Investing.com South Africa
Clear Street Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Janux Therapeutics stock price target lowered to $45 by H.C. Wainwright - Investing.com South Africa
Janux Therapeutics stock price target lowered to $150 by Cantor Fitzgerald - Investing.com Nigeria
Truist Securities reiterates Buy rating on Janux Therapeutics stock By Investing.com - Investing.com South Africa
Apple, Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Stock Movers: Boeing, Janux Therapeutics, Signet - Bloomberg.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Investors flee Janux after updated prostate cancer results disappoint - FirstWord Pharma
Janux Therapeutics stock hits 52-week low at 18.34 USD By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Janux T-cell engager data sink stock, but analysts still see best-in-class potential - Fierce Biotech
Janux dives as gaps in prostate cancer study data worry investors - MSN
Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair - BioPharma Dive
Janux stock falls as UBS maintains Buy rating despite disappointing data - Investing.com Nigeria
Janux Therapeutics (JANX) Stock: Why Did Shares Crash 41% on "Positive" News? - parameter.io
Applovin, MongoDB among market cap stock movers on Tuesday By Investing.com - Investing.com South Africa
Applovin, MongoDB among market cap stock movers on Tuesday - Investing.com
Truist Securities reiterates Buy rating on Janux Therapeutics stock - Investing.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Marvell, and More Movers - Barron's
Biggest stock movers Tuesday: CRDO, MDB, BA, and more - Seeking Alpha
Janux lets the genie out of the bottle | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings - Benzinga
Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Stocks Edge Higher As Traders Wait For Key Inflation Data - Finimize
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Apple, MongoDB, Credo, Warner Bros. Discovery, Janux, Marvell, and More Movers - Barron's
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Drug Trial Data. Why It’s Down 41%. - Barron's
Janux Therapeutics stock price target lowered to $45 by H.C. Wainwright By Investing.com - Investing.com India
Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright - TipRanks
Janux Therapeutics price target lowered to $49 from $58 at BofA - TipRanks
0.18%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):